{"id":"W3095852744","doi":"10.15326/jcopdf.2020.0158","title":"InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions","year":2020,"lang":"en","type":"article","venue":"Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Sanofi Genzyme; Pearl Therapeutics; Genentech; Grifols; Mylan; Regeneron Pharmaceuticals; Boston Scientific Corporation; Sunovion; Gilead Sciences; Galderma; York University; AstraZeneca; Dartmouth College; Chiesi Farmaceutici; Sanofi; Medical Research Council; Biogen; GlaxoSmithKline; Veracyte; Teva Pharmaceutical Industries; National Heart, Lung, and Blood Institute; American Thoracic Society","keywords":"Medicine; Fluticasone propionate; Dry-powder inhaler; COPD; Inhaler; Internal medicine; Asthma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002171297,0.0006817751,0.001449286,0.000198747,0.0002500008,0.000810504,0.0004030051,0.0007979008,0.003319943],"category_scores_gemma":[0.002045123,0.000230694,0.001633418,0.0003092767,0.0005277749,0.0004430288,0.000459117,0.001595688,0.0001982638],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004940272,"about_ca_system_score_gemma":0.001227935,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008706996,"about_ca_topic_score_gemma":0.001661937,"domain_scores_codex":[0.9990463,0.0006434963,0.00005294753,0.00008621585,0.00007687629,0.00009406065],"domain_scores_gemma":[0.9987626,0.0003729454,0.0003851643,0.0000671863,0.0000850064,0.000327064],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9495463,0.005791239,0.00415038,0.001422363,0.002489398,0.00002492068,0.00008410666,0.0009615507,0.002093538,0.0001397663,0.0007313704,0.03256514],"study_design_scores_gemma":[0.8946153,0.08765787,0.01178115,0.0001765666,0.003355952,0.00004864049,0.00004955544,0.0005643707,0.0007535553,0.0001776503,0.0008036278,0.00001575751],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898133,0.005507209,0.0003442907,0.0004842431,0.0001306055,0.001398083,0.0004853671,0.00002952083,0.001807409],"genre_scores_gemma":[0.9930834,0.002338304,0.001288118,0.0004299037,0.0001702235,0.001244037,0.000625319,0.000006011139,0.0008147347],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003319943,"threshold_uncertainty_score":0.01148301,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03244249774097455,"score_gpt":0.2780959886263978,"score_spread":0.2456534908854233,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}